London-based WEP Clinical Selects bioaccess.™ As Market Access Consultant to Enter the Colombian Market and Provide Patients Access to Life-Savings Drugs

 WEP Clinical Selects BIOACCESS™ as its Market Access Consultant to Enter the Colombian Market

[Orlando, FL, August 22, 2018] — WEP Clinical —a London-based drug sourcing, and distribution company— has selected bioaccess.™ as its market access, regulatory and business development consultant to enter the Colombian market for hard-to-find drugs. For hospitals or health management organizations (HMOs) that want to provide a life-saving and hard-to-find drug to their patients, WEP Clinical offers an efficient, end-to-end product distribution model. From the required regulatory filings, through to product handling and delivery, WEP Clinical is well positioned to support patient's needs.

Established in 2008, WEP Clinical is a specialist services company that helps patients and physicians get access to medicines when no other treatment options are available. With nearly 10 years of experience and a global reach, WEP Clinical is passionate about helping those in need. With offices located in the Research Triangle Park area in North Carolina, USA; and London, United Kingdom, WEP Clinical's staff provides global solutions to meet the drug access or distribution needs or hospitals in over 60 countries. 

WEP Clinical is looking to expand its market reach to Latin America and considers Colombia one of its key target markets along with Brazil and Mexico. bioaccess.™ will assist WEP Clinical with its plan to enter the Colombian market. For this, bioaccess.™ will deploy its local resources in Colombia to operationalize a business development strategy that it will create for WEP Clinical with the sole goal to have WEP Clinical establish a strong local presence sell its products/services in Colombia.

When Colombian patients need a special drug that is not commercially available in Colombia yet, the patient needs to find a way to buy the drug from an overseas supplier or somehow have its HMO find it; for this, the patient or the HMO need to apply for a special import permit from INVIMA —Colombia's drug regulatory agency. This special import permit is given under an efficient Named Patient Program that is worth about USD $6M annually in Colombia; the program is called Medicamentos Vitales no Disponibles and is regulated by INVIMA. Since its inception, there are 142 drugs already included under the program. Under this program, INVIMA receives about 1,300 annual special import permit approval applications and approves about 80% of them. 

WEP Clinical has engaged bioaccess.™ to help the company establish a presence in Colombia and perform business development activities conducive to helping patients have easier and faster access to life-saving drugs under the Medicamentos Vitales no Disponibles program. 

About WEP Clinical

Established in 2008, WEP Clinical is a specialist services company that helps patients and physicians get early access to medicines when no other treatment options are available. With nearly 10 years of experience and a global reach, the company is passionate about helping those in need. With offices located in RTP, North Carolina, and London, the United Kingdom, WEP Clinical's staff provide global solutions to meet hospitals' drug access or distribution needs. On behalf of its customers, WEP Clinical's team supports patients and physicians in over 60 countries around the world.

About bioaccess.™

bioaccess.™ is a Florida-based clinical research organization (CRO) and market access consulting company which mission is to help innovative life science companies conduct clinical research and commercialize their innovations in Latin America. More information at www.bioaccessla.com.

###

bioaccess.™ Press Contact:

Julio G. Martinez-Clark, CEO
Tel: +1 (954) 903-7210
Email: jmclark@bioaccessla.com